Motion · S2M-03404 · 7 Oct 2005

HER-2 Testing: Herceptin Treatment for Breast Cancer

Lodged by Dr Jean Turner Standard Motion 18 supporters

The motion

That the Parliament congratulates the Department of Health for announcing that all patients with breast cancer must be prospectively tested for HER-2 gene status; applauds Professor Mike Richards for meeting the leaders of all cancer networks in England to lay down a timetable so that all patients will be tested in readiness for the availability of Herceptin within the next six months; also congratulates the Scottish Executive for putting in place similar plans for Scotland; notes that the important emphasis now is that HER-2 testing, at the point of diagnosis, is vital to avoid progression of the disease into metastatic advancement, and recognises that approximately 805 HER-2 positive patients in Scotland could benefit from Herceptin, allowing them a better quality of life and perhaps a chance to live longer.

Supporters (18)

Source: the Scottish Parliament motions and amendments record.